This page is dedicated to the Infantile Esotropia research study, one of 57 studies supported by the Boston Children’s Rare Disease Collaborative (CRDC). For more information about the CRDC, please visit our home page. Established in 2018, the CRDC supports pediatric rare disease research and provides families with genetic diagnoses that enable personalized treatments, including precision medicine and targeted therapies.
The Infantile Esotropia research study, established at Boston Children’s in 2022 and led by Dr. Mary Whitman, has already enrolled 25 patients and their families. The study aims to identify genetic causes of infantile esotropia and provide personalized medicine.